Company: TELO
Filing Date: 2025-03-19
Form Type: 8-K
Source: 0001493152-25-010868
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-03-19
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer
Cells

Telomir-1
Inhibits Tumor Growth, Suppresses Cancer Progression, and Neutralizes Chemotherapy Toxicity

Telomir
Pharmaceuticals, Inc. (NASDAQ: TELO) (“ Telomir”), a leader in age-reversal science, today announced groundbreaking preclinical
findings demonstrating that Telomir-1 reduces tumor size by approximately 50% in a prostate cancer animal model using highly aggressive
human prostate cancer cells. It actively suppresses cancer growth rather than promoting it, and protects against chemotherapy-induced
toxicity and mortality when combined with Paclitaxel - a widely used chemotherapy drug known for its effectiveness in treating various
cancers but often associated with severe toxicity and side effects.

Key
findings include:

1.
Telomir-1 alone at both low and high doses reduced tumor growth by approximately 50%.

2.
Contrary to concerns that telomere-elongating drugs may promote cancer, Telomir-1 demonstrated the opposite effect - actively suppressing
tumor development while selectively benefiting healthy cells.

3.
In the group treated with Paclitaxel alone, severe toxicity was observed, leading to significant weight loss and mortality of one-third
of the animals. However, when low-dose Telomir-1 was added to Paclitaxel, no mortality occurred.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                      TELOMIR                                      
  Dated:              By:                       /s/                
                      Name:                     Erez               
                      Title:                    Chief